Coma and respiratory depression following the ingestion of GHB and its precursors: Three cases

Journal of Emergency Medicine

Volumn 19, Issue 1, 2000, Pages 47-50

  Ingels, Marianne ^a,b   Rangan, Cyrus ^a,b   Bellezzo, Joseph ^a   Clark, Richard F ^a,b  

^a UCSD MEDICAL CENTER   (United States)

^b California Poison Control System   (United States)

Author keywords

1,4 Butanediol; Apnea; Coma; Gamma butyrolactone; Gamma hydroxybutyrate

Indexed keywords

1,4 BUTANEDIOL; 4 HYDROXYBUTYRIC ACID; ALCOHOL; COCAINE; GAMMA BUTYROLACTONE; METHAMPHETAMINE; PARACETAMOL; SALICYLIC ACID DERIVATIVE; TETRAHYDROCANNABINOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CASE REPORT; COMA; DRUG ABUSE; HUMAN; MALE; PRIORITY JOURNAL; RESPIRATION DEPRESSION; URINALYSIS;

ADULT; CENTRAL NERVOUS SYSTEM DEPRESSANTS; COMA; HUMANS; MALE; MIDDLE AGED; RESPIRATORY INSUFFICIENCY; SODIUM OXYBATE; SUBSTANCE-RELATED DISORDERS;

EID: 0034237236     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0736-4679(00)00188-8     Document Type: Article

References (16)

1. CDC . Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate. MMWR. 39:1990;861-863.
2. Statement by Nicholas Reuter, MPH-March 11, 1999. http://www.fda.gov/ola/substance.htm.
3. FDA. FDA warns about products containing gamma butyrolactone or GBL and asks companies to issue a recall. January 21, 1999.
4. FDA. FDA warns about GBL-related products. May 11, 1999.
5. Takahara J., Yunoki S., Yakushiji W., et al. Stimulatory effects of γ-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab. 44:1977;1014-1017.
6. CDC . Gamma hydroxy butyrate use. MMWR. 46:1997;281-283.
7. Lettieri J., Fung H.L. Improved pharmacological activity via pro-drug modification comparative pharmacokinetics of sodium γ-hydroxybutyrate and γ-butyrolactone . Res Commun Chem Path Pharmacol. 22:1978;107-118.
8. Roth R.H., Giarman N.J. Preliminary report on the metabolism of γ-butyrolactone and γ-hydroxybutyric acid. Biochem Pharmacol. 14:1965;177-178.
9. Roth R.H., Delgado J.M.R., Giarman N.J. γ-Butyrolactone and γ-hydroxybutyric acid-II. The pharmacologically active form. Int J Neuropharmacol. 5:1966;421-428.
10. Guidotti A., Ballotti P.L. Relationship between pharmacological effects and blood and brain levels of γ-butyrolactone and γ-hydroxybutyrate. Biochem Pharmacol. 19:1970;883-894.
11. Arena C., Fung H.L. Absorption of sodium γ-hydroxybutyrate and its prodrug γ-butyrolactone relationship between in vitro transport and in vivo absorption . J Pharmaceut Sci. 69:1980;356-358.
12. Higgins T., Borron S. Coma and respiratory arrest after exposure to butyrolactone. J Emerg Med. 14:1996;435-437.
13. Rambourg-Schepens M.O., Buffet M., Durak C., et al. Gamma butyrolactone poisoning and its similarities to gamma hydroxybutyric acid two case reports . Vet Human Toxicol. 39:1997;234-235.
14. CDC . Adverse events associated with ingestion of γ-butyrolactone. MMWR. 48:1999;137-140.
15. Poldrugo F., Snead O.C. 1,4 Butanediol, γ-hydroxybutyric acid and ethanol relationships and interactions . Neuropharmacology. 23:1984;109-113.
16. Dyer J.E., Galbo M.J., Andrews K.M. 1,4-Butanediol, "pine needle oil" overdose mimics toxic profile of GHB . J Toxicol Clin Toxicol. 35:1997;554. [abstract].